NIKP-Rabeprazole

NIKP-Rabeprazole Dosage/Direction for Use

rabeprazole

Manufacturer:

Nichi-Iko

Distributor:

DKSH
Full Prescribing Info
Dosage/Direction for Use
Adults / elderly: Duodenal Ulcer, Gastric Ulcer, Stomal Ulcer & Reflux Esophagitis: The usual adult dose is 10 mg of rabeprazole sodium administered orally once daily. However, the dosage may be increased up to 20 mg orally once a day depending on the severity of symptoms. For the treatment of gastric ulcer, stomal ulcer and reflux esophagitis, the usual administration should be restricted up to 8 weeks, and for duodenal ulcer, 6 weeks.
Gastro-Esophageal Reflux Disease Long-term Management (GERD Maintenance): For long-term management, a maintenance dose of NIKP-Rabeprazole enteric coated tablet 10mg or 20mg once daily can be used depending upon patient response.
Symptomatic Treatment of Moderate to Very Severe Gastro-Esophageal Reflux Disease (symptomatic GERD): 10 mg once daily in patients without esophagitis.
If symptom control has not been achieved during four weeks, the patient should be further investigated. Once symptoms have resolved, subsequent symptom control can be achieved using an on-demand regimen taking 10 mg once daily when needed.
Zollinger-Ellison Syndrome: The dose varies with the individual patient. A starting dose of 60 mg daily, and doses of up to 100 mg once daily, or 60 mg twice daily have been used. Some patients may require divided doses. Dosing should continue for as long as clinically necessary. Some patients with Zollinger-Ellison Syndrome have been treated continuously for up to one year.
Eradication of H. pylori: Patients with H. pylori infection should be treated with eradication therapy. The following combination given for 7 days is recommended: NIKP-Rabeprazole enteric coated tablet 20 mg twice daily + clarithromycin 500 mg twice daily and amoxicillin 1 g twice daily.
For indications requiring once daily treatment, NIKP-Rabeprazole enteric coated tablet should be taken in the morning, before eating; and although neither the time of day nor food intake was shown to have any effect on rabeprazole sodium activity, this regimen will facilitate treatment compliance.
Patients should be cautioned that the NIKP-Rabeprazole enteric coated tablet should not be chewed or crushed, but should be swallowed whole.
Renal and hepatic impairment: No dosage adjustment is necessary for patients with renal or hepatic impairment.
See Precautions for use of NIKP-Rabeprazole enteric coated tablet in the treatment of patients with hepatic impairment.
Children: NIKP-Rabeprazole enteric coated tablet is not recommended for use in children, as there is no experience of its use in this group.
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in